Originally, this was a Reuters report, but now Bloomberg is carrying it, as well:
. . . .Sanofi-Aventis SA agreed to buy Merck & Co.’s stake in their Merial animal-health venture to help the French drugmaker weather generic competition to its best-selling drugs, said two people familiar with the situation.
The acquisition is set to be announced this week, said the people, who declined to be identified as an official announcement hasn’t been made. They didn’t disclose the price of the transaction. The stake may be worth about 2 billion euros ($2.8 billion), according to Eric Le Berrigaud, an analyst at Raymond James in Paris. . . .
We shall see. At least to my understanding, it would not preclude a deal for some parts of Intervet -- though it would make a large deal, on that front, rather unlikely.